C:\Program Files\Stnexp\Queries\10568052 (b).str





```
chain nodes :
    7  8  9  10  12  14
ring nodes :
    1  2  3  4  5  6
chain bonds :
    1-7  3-8  7-14  7-12  9-10
ring bonds :
    1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
    1-7  7-14  7-12  9-10
exact bonds :
    3-8
normalized bonds :
    1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
    containing 1 :


G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:Atom  12:Atom
    14:CLASS  16:Atom
Generic attributes :
    9:
    Saturation              : Unsaturated
    Number of Carbon Atoms : less than 7
    10:
    Saturation              : Unsaturated
    12:
    Saturation              : Unsaturated

Element Count :
    Node 9: Limited
        C,C1-5
```

=>
Uploading C:\Program Files\Stnexp\Queries\10568052.str





chain nodes :
7 8 9 10 12 14
ring nodes :
1 2 3 4 5 6
chain bonds :
1-7 3-8 6-9 7-12 7-14 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-7 6-9 7-12 7-14 9-10
exact bonds :
3-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:Atom
12:Atom  14:CLASS
Generic attributes :
9:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7
10:
Saturation              : Unsaturated
12:
Saturation              : Unsaturated

Element Count :
Node 9: Limited
    C,C1-5



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 H,Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu


Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 23:53:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    32459 TO ITERATE

  6.2% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
```

```
                          BATCH    **COMPLETE**
PROJECTED ITERATIONS:        638407 TO   659953
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10568052 (a).str
```





```
chain nodes :
7  8  9  10  12  14
ring nodes :
1  2  3  4  5  6
chain bonds :
3-8  7-14  7-12  9-10
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
7-14  7-12  9-10
exact bonds :
3-8
normalized bonds :
```

```
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:Atom
12:Atom  14:CLASS  16:Atom  17:Atom
Generic attributes :
9:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7
10:
Saturation              : Unsaturated
12:
Saturation              : Unsaturated

Element Count :
Node 9: Limited
    C,C1-5




L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3              STR
```




```
G1 H,Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu


Structure attributes must be viewed using STN Express query preparation.


=> s l3 sss sam
SAMPLE SEARCH INITIATED 23:54:33 FILE 'REGISTRY'
```

```
SAMPLE SCREEN SEARCH COMPLETED -    68280 TO ITERATE

  2.9% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1350033 TO  1381167
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1840

L5    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L6    SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10568052 (b).str
```





chain nodes :
7 8 9 10 12 14
ring nodes :
1 2 3 4 5 6
chain bonds :
1-7 3-8 7-14 7-12 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-7 7-14 7-12 9-10
exact bonds :
3-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:Atom
12:Atom  14:CLASS  16:Atom
Generic attributes :
9:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7
10:
Saturation              : Unsaturated
12:
Saturation              : Unsaturated

Element Count :
Node 9: Limited
    C,C1-5




L7      STRUCTURE UPLOADED

=> que L7 AND L5 NOT L6

L8   QUE L7 AND L5 NOT L6

=> d 18
L8 HAS NO ANSWERS
L5                SCR 1840
L6                SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L7                STR
```




```
G1 H,Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu


Structure attributes must be viewed using STN Express query preparation.
L8                QUE  L7 AND L5 NOT L6


=> s l8 sss sam
SAMPLE SEARCH INITIATED 23:57:00 FILE 'REGISTRY'
```

```
SAMPLE SCREEN SEARCH COMPLETED -    23364 TO ITERATE

  8.6% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       458131 TO   476429
PROJECTED ANSWERS:               0 TO        0

L9            0 SEA SSS SAM L7 AND L5 NOT L6

=> s l8 sss ful
FULL SEARCH INITIATED 23:57:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   470310 TO ITERATE

100.0% PROCESSED   470310 ITERATIONS                           165 ANSWERS
SEARCH TIME: 00.00.08

L10         165 SEA SSS FUL L7 AND L5 NOT L6

=> => s l10
L11           9 L10

=> d 111 1-9 bib,ab,hitstr
```

L11 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1249826 CAPLUS
DN 146:781
TI Methods of treating pain
IN Wabnitz, Philipp; Schauerte, Heike; Stumm, Gabriele; Freitag, Joachim
PA Ingenium Pharmaceuticals A.-G., Germany
SO PCT Int. Appl., 132pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006125616	A2	20061130	WO 2006-EP4924	20060524
WO 2006125616	A3	20070419		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1901747	A2	20080326	EP 2006-743044	20060524
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI US 2005-684345P	P	20050525		
WO 2006-EP4924	W	20060524		

OS MARPAT 146:781
AB The invention relates to methods of treating any type of pain comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
IT 848636-45-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating pain)
RN 848636-45-3 CAPLUS
CN Benzamide, 4-amino-N-[4-[[6-(2-phenylethenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1065980 CAPLUS
DN 145:419166
TI Preparation of pyrimidine derivatives as tyrosine kinase inhibitors
IN Shiota, Takeshi; Suzuki, Naoyuki; Murashi, Takami
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 117pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006106721	A1	20061012	WO 2006-JP306445	20060329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI JP 2005-97361	A	20050330		

OS MARPAT 145:419166
AB Title compds. I [R1 = alkyl, alkyloxy, alkylthio, etc.; R2 = Q1, etc.; R4, R5 = H, (un)substituted alkyl, alkenyl, etc.; R6 = (un)substituted alkyl, alkyloxy, alkoxycarbonyl, etc.; Ar1 = arylene, heteroarylene; R = (un)substituted alkyl, alkyloxy, alkyloxycarbonyl, etc.; n = 0-2; Y = -O-, -S-, -NR20-, etc.; R20 = H, alkyl, acyl, etc.; R3 = Q2, etc.; R22 = H, halo, (un)substituted alkyloxy, etc.; R23, R24 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.], pharmaceutically acceptable salts or solvates thereof were prepared For example, reaction of 4-chloro-5-iodo-6-methylpyrimidine with 3-chloro-4-(3-fluorobenzyloxy)aniline followed by Pd(PPh3)2Cl2 catalyzed coupling with 4-but-3-ynyl-morpholine afforded compound II. In tyrosine kinase inhibition assays, compound II exhibited IC50 values of 19 and 74 nM against EGFR and HER2, resp. Compds. I are claimed useful for the treatment of cancer.
IT 912354-53-1P 912354-54-2P 912354-55-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as tyrosine kinase inhibitors for treatment of cancer)
RN 912354-53-1 CAPLUS
CN Benzoic acid, 4-[(1E)-2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethenyl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 912354-54-2 CAPLUS
CN Benzenemethanol, 4-[(1E)-2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 912354-55-3 CAPLUS
CN Benzaldehyde, 4-[(1E)-2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 912353-86-7P 912353-87-8P 912353-88-9P
912353-89-0P 912353-90-3P 912353-91-4P
912353-95-8P 912353-96-9P 912353-97-0P
912353-98-1P 912353-99-2P 912354-00-8P
912354-01-9P 912354-07-5P 912354-09-7P
912354-11-1P 912354-13-3P 912354-14-4P
912354-16-6P 912354-18-8P 912354-20-2P
912354-21-3P 912354-22-4P 912354-23-5P
912354-25-7P 912354-26-8P 912354-27-9P
912354-28-0P 912354-30-4P 912354-32-6P
912354-34-8P 912354-45-1P 912354-91-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as tyrosine kinase inhibitors for treatment of cancer)

RN 912353-86-7 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[4-(4-morpholinylmethyl)phenyl]ethynyl]- (CA INDEX NAME)



RN 912353-87-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[3-(4-morpholinylmethyl)phenyl]ethynyl]- (CA INDEX NAME)



RN 912353-88-9 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-[[(1-methylethyl)amino]methyl]-2-furanyl]ethynyl]- (CA INDEX NAME)



RN 912353-89-0 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(4-morpholinylmethyl)-2-furanyl]ethynyl]- (CA INDEX NAME)



RN 912353-90-3 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]ethynyl]- (CA INDEX NAME)



RN 912353-91-4 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[(4-ethyl-1-piperazinyl)methyl]-2-thiazolyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912353-95-8 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(4-morpholinylmethyl)-2-thiazolyl]ethynyl]- (CA INDEX NAME)



RN 912353-96-9 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(1-pyrrolidinylmethyl)-2-furanyl]ethynyl]- (CA INDEX NAME)



RN 912353-97-0 CAPLUS
CN 3-Pyrrolidinol, 1-[[4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethynyl]phenyl]methyl]- (CA INDEX NAME)



RN 912353-98-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[[(3-methoxypropyl)amino]methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912353-99-2 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[[(2-methoxyethyl)amino]methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-00-8 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-[(dimethylamino)methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-01-9 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[3-[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)



RN 912354-07-5 CAPLUS
CN 2-Furanmethanol, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 912354-09-7 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[(cyclopropylamino)methyl]-2-furanyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-11-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(4-morpholinylmethyl)-2-thienyl]ethynyl]- (CA INDEX NAME)



RN 912354-13-3 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[5-(1-pyrrolidinylmethyl)-2-thienyl]ethynyl]- (CA INDEX NAME)



RN 912354-14-4 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[(dimethylamino)methyl]-2-furanyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-16-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[(methoxymethylamino)methyl]-2-furanyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-18-8 CAPLUS
CN 2-Furancarboxaldehyde, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-methyl-5-pyrimidinyl]ethynyl]-, O-methyloxime (CA INDEX NAME)



RN 912354-20-2 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[4-(1-pyrrolidinylmethyl)phenyl]ethynyl]- (CA INDEX NAME)



RN 912354-21-3 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[2-[4-[[(1-methylethyl)amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)



RN 912354-22-4 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[(dimethylamino)methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-23-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-

5-[2-[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)



RN 912354-25-7 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[(ethylamino)methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-26-8 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-fluoro-4-[[(1-methylethyl)amino]methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-27-9 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-fluoro-4-[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-28-0 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-fluoro-4-(4-morpholinylmethyl)phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-30-4 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-fluoro-4-(1-pyrrolidinylmethyl)phenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-32-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[(dimethylamino)methyl]-3-fluorophenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-34-8 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[4-[(ethylamino)methyl]-3-fluorophenyl]ethynyl]-6-methyl- (CA INDEX NAME)



RN 912354-45-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-5-[(1E)-2-[4-(4-morpholinylmethyl)phenyl]ethenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

● HCl

RN 912354-91-7 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-methyl-

5-[2-[5-[[(1-methylethyl)amino]methyl]-3-furanyl]ethynyl]- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:274296 CAPLUS
DN 144:488615
TI Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors
AU Waterson, Alex G.; Stevens, Kirk L.; Reno, Michael J.; Zhang, Yue-Mei; Boros, Eric E.; Bouvier, Frederic; Rastagar, Abdullah; Uehling, David E.; Dickerson, Scott H.; Reep, Bryan; McDonald, Octerloney B.; Wood, Edgar R.; Rusnak, David W.; Alligood, Krystal J.; Rudolph, Sharon K.
CS GlaxoSmithKline, Research Triangle Park, NC, 27709-3398, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(9), 2419-2422
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:488615
AB Anilinoalkynylpyrimidines were prepared and evaluated as dual EGFR/ErbB2 kinase inhibitors. A preference was found for substituted Ph and heteroarom. rings attached to the alkyne. In addition, the presence of a potential hydrogen bond donor appended to this ring was favored. Selected mols. in the series demonstrated some activity against human tumor cell lines.
IT 845657-38-7P 845657-48-9P 845657-82-1P
845658-03-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors)
RN 845657-38-7 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(3-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845657-48-9 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(4-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845657-82-1 CAPLUS
CN 2-Pyridinemethanol, 6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845658-03-9 CAPLUS
CN 4-Pyrimidinamine, 5-[2-[6-(aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



IT 845657-23-0P 845657-32-1P 845657-39-8P
845657-45-6P 845657-47-8P 845657-53-6P
845657-57-0P 845657-58-1P 845657-74-1P
845658-08-4P 845658-12-0P 845658-25-5P
887147-46-8P 887147-47-9P 887147-48-0P
887147-49-1P 887147-50-4P 887147-51-5P
887147-52-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors)
RN 845657-23-0 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-pyridinyl)ethynyl]- (CA INDEX NAME)



RN 845657-32-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-pyrimidinyl)ethynyl]- (CA INDEX NAME)



RN 845657-39-8 CAPLUS
CN Acetamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-45-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-(2-phenylethynyl)- (CA INDEX NAME)



RN 845657-47-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-pyridinyl)ethynyl]- (CA INDEX NAME)



RN 845657-53-6 CAPLUS
CN Acetamide, N-[[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]methyl]- (CA INDEX NAME)



RN 845657-57-0 CAPLUS
CN 2-Furanmethanol, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-58-1 CAPLUS
CN 2-Thiazolemethanol, 4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-74-1 CAPLUS
CN Acetamide, N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]- (CA INDEX NAME)



RN 845658-08-4 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)



RN 845658-12-0 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-methyl- (CA INDEX NAME)



RN 845658-25-5 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(2-amino-4-pyrimidinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 887147-46-8 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(2-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 887147-47-9 CAPLUS
CN Acetamide, N-[4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 887147-48-0 CAPLUS
CN Methanesulfonamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 887147-49-1 CAPLUS
CN Benzamide, 3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-N-methyl- (CA INDEX NAME)



RN 887147-50-4 CAPLUS
CN Propanamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-3-(methylsulfonyl)- (CA INDEX NAME)



RN 887147-51-5 CAPLUS
CN Pentanoic acid, 5-[[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]amino]-5-oxo-, methyl ester (CA INDEX NAME)



RN 887147-52-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(1H-pyrazol-3-yl)ethynyl]- (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1314844 CAPLUS
DN 144:36371
TI Preparation of fused heterocyclic compounds as tyrosine kinase inhibitors
IN Ishikawa, Tomoyasu; Taniguchi, Takahiko; Banno, Hiroshi; Seto, Masaki
PA Takeda Pharmaceutical Company Limited, Japan
SO PCT Int. Appl., 555 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005118588	A1	20051215	WO 2005-JP10451	20050601
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005250285	A1	20051215	AU 2005-250285	20050601
	CA 2569016	A1	20051215	CA 2005-2569016	20050601
	EP 1752457	A1	20070214	EP 2005-748463	20050601
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1993362	A	20070704	CN 2005-80026187	20050601
	BR 2005011768	A	20080108	BR 2005-11768	20050601
	US 20070244132	A1	20071018	US 2006-592812	20060914
	MX 2006PA13996	A	20070208	MX 2006-PA13996	20061130
	IN 2006KN03798	A	20070615	IN 2006-KN3798	20061218
	NO 2006006015	A	20070213	NO 2006-6015	20061227
PRAI	JP 2004-165050	A	20040602		
	JP 2005-58231	A	20050302		
	WO 2005-JP10451	W	20050601		

OS MARPAT 144:36371
AB Fused heterocyclic compds. such as 1H-pyrazolo[4,3-d]pyrimidine and 5H-pyrrolo[3,2-d]pyrimidine represented by the formula (I) [wherein W = C(R1) or N; A = each optionally substituted aryl or heteroaryl; X1 = NR3-Y1, O, S, SO, SO2, CHR3 (wherein R3 = H or optionally substituted aliphatic hydrocarbon group, provided that R3 may be bonded to A to form an optionally substituted ring structure); R1 = H or optionally substituted group bonded through a carbon, nitrogen, or oxygen atom; R2 = H or optionally substituted group bonded through a carbon or sulfur atom, provided that R2 may be bonded to R1 or R3 to form an optionally substituted ring structure] or salts thereof are prepared A tyrosine kinase inhibitor or a preventive/therapeutic agent for cancers which each contains the compound I or a prodrug thereof is provided. Thus, a solution of 100 mg 4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine in 1.0 mL 1-methyl-2-pyrrolidone was treated with 225 mg 3-chloro-4-[(3-fluorobenzyl)oxy]aniline and heated at 140° with stirring for 1.5 h

to give, after workup and silica gel chromatog., 121 mg N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (II). II at 1.0 μM in vitro inhibited 96.1% HER 2 kinase. Pharmaceutical tablet formulations containing II were prepared

IT 871023-81-3P 871023-83-5P 871023-91-5P
871025-29-5P 871025-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused heterocyclic compds. as tyrosine kinase inhibitors and preventive/therapeutic agent for cancers)

RN 871023-81-3 CAPLUS
CN 4,5-Pyrimidinediamine, 6-[2-(3-aminophenyl)ethynyl]-N4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)



RN 871023-83-5 CAPLUS
CN 4,5-Pyrimidinediamine, 6-[2-(4-aminophenyl)ethynyl]-N4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)



RN 871023-91-5 CAPLUS
CN Carbamic acid, [[3-[[5-amino-6-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]ethynyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 871025-29-5 CAPLUS

CN 4,5-Pyrimidinediamine, 6-[2-(3-aminophenyl)ethynyl]-N4-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 871025-32-0 CAPLUS
CN 4,5-Pyrimidinediamine, 6-[2-(4-aminophenyl)ethynyl]-N4-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:588667 CAPLUS
DN 143:115556
TI Preparation of 4-aminopyrimidine derivatives as inhibitors of Tie2 receptor tyrosine kinases
IN Jones, Clifford David; Luke, Richard William Arthur; McCoull, William
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005060969	A1	20050707	WO 2004-GB5332	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1737462	A1	20070103	EP 2004-806134	20041220
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1917880	A	20070221	CN 2004-80041936	20041220
	JP 2007517006	T	20070628	JP 2006-546305	20041220
	US 20080027076	A1	20080131	US 2006-596740	20060622
	IN 2006MN00847	A	20070420	IN 2006-MN847	20060717
PRAI	GB 2003-30001	A	20031224		
	GB 2004-16850	A	20040729		
	WO 2004-GB5332	W	20041220		

OS CASREACT 143:115556; MARPAT 143:115556
AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, urea II was synthesized in 21% yield by condensation of the corresponding aniline with Ph thiadiazolylcarbamate in the presence of Et3N in THF under microwave irradiation This urea showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC50 values of 0.879 μM and 5.557 μM, resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.
IT 857287-38-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(5-tert-butylisoxazol-3-yl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)
RN 857287-38-8 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:260034 CAPLUS
DN 142:336376
TI Preparation of pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
IN Choidas, Axel; Backes, Alexander; Cotten, Matt; Engkvist, Ola; Felber, Beatrice; Freisleben, Achim; Godl, Klaus; Greff, Zoltan; Habenberger, Peter; Hafenbradl, Doris; Hartung, Christian; Herget, Thomas; Hoppe, Edmund; Klebl, Bert; Missio, Andrea; Mueller, Gerhard; Schwab, Wilfried; Zech, Birgit; Bravo, Jose; Harris, John; Le, Joelle; Macritchie, Jackie; Savic, Vladimir; Sherborne, Brad; Simpson, Don; Simpson, Don
PA Axxima Pharmaceuticals AG, Germany
SO PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026129	A1	20050324	WO 2004-EP10353	20040915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1678147	A1	20060712	EP 2004-786953	20040915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20070191344	A1	20070816	US 2006-572043	20061212
PRAI	EP 2003-20888	A	20030915		
	US 2003-504527P	P	20030922		
	EP 2004-10308	A	20040430		
	US 2004-569806P	P	20040512		
	WO 2004-EP10353	W	20040915		

OS CASREACT 142:336376; MARPAT 142:336376
AB The invention is related to the preparation of title compds. I, and/or stereoisomeric forms and/or pharmaceutically acceptable salts [wherein R1 = H, (un)substituted alk(en/yn)yl; R2, R4 = independently H, F, Cl, Br, I, CN, NH2, NO2, (un)substituted alk(en/yn)yl; R3 = F, Cl, Br, I, (un)substituted hetero/aryl, etc.; X = R5-[LR6]m; R5 = (un)substituted hetero/aryl, heterocyclyl, cycloalkyl, etc.; R6 = H, (un)substituted alkyl, hetero/aryl, heterocyclyl, etc.; L = NRSO2, NRSO; R = H, (un)substituted alkyl, SO2-alkyl, etc.] as protein kinase inhibitors for use in the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunol. diseases, autoimmune diseases, bipolar and clin. disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke. The invention is also related to a medium comprising at least one of compds. I in an immobilized form and its use for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized I.

General preparation procedures and 5 individual synthetic examples are given. I have an inhibitory effect on the protein kinase activity of various protein kinases, such as Abl, CDK1, CDK5, etc. Selected I had an inhibitory effect on CDK9 and CDK2 with IC50 values in the range of 1 to 1000 nM. I were potent inhibitors of HIV and HCMV replication in cell cultures; for example II showed inhibition of HCMV replication in HFF cells.

IT 848636-45-3P, 4-Amino-N-[4-(6-styrylpyrimidin-4-ylamino)phenyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)

RN 848636-45-3 CAPLUS

CN Benzamide, 4-amino-N-[4-[[6-(2-phenylethenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:158661 CAPLUS
DN 142:240460
TI Preparation of pyrimidine derivatives as ErbB kinase inhibitors
IN Reno, Michael John; Stevens, Kirk Lawrence; Waterson, Alex Gregory; Zhang, Yuemei
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016914	A1	20050224	WO 2004-US26251	20040811
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1654251	A1	20060510	EP 2004-781004	20040811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007502298	T	20070208	JP 2006-523388	20040811
	US 20060205740	A1	20060914	US 2006-568052	20060210
PRAI	US 2003-495180P	P	20030814		
	WO 2004-US26251	W	20040811		

OS CASREACT 142:240460; MARPAT 142:240460
AB Title compds. I [wherein A = alkenylene, alkynylene; R = alkylene; R1 = -(Z)-(Z1)m-(Z2)n; Z = hetero/aryl, hetero/arylene; Z1 = CH2 where m = 0-1; Z2 = OH and derivs., halo, CN, CONH2 and derivs. or heterocyclyl, where n = 0-1, etc.; R2 = H, alkyl; R3 = -(Q)-(Q1)r-(Q2); Q = hetero/arylene; Q1 = O, where r = 0-1; Q2 = arylalkyl, hetero/aryl; and their salts, solvates, and physiol. functional derivs.] were prepared as ErbB kinase inhibitors for treating cancer. Thus, reacting 2-benzyl-N-(5-vinylpyrimidin-4-yl)-1H-benzimidazol-5-amine (preparation given) with Ph iodide gave pyrimidine II in 8%. I showed inhibitory activity vs. EGFR, ErbB-2, and ErbB-4 protein tyrosine kinases with a pIC50 ≥ 5.0. I are useful in the treatment of diseases associated with inappropriate ErbB family kinase activity.
IT 845657-38-7P, 5-[(3-Aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]pyrimidin-4-amine 845657-39-8P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-51-4P, tert-Butyl [[3-[[4-[[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]methyl]carbamate 845657-55-8P, 5-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]-2-furaldehyde 845657-72-9P, 5-[(6-Amino-2-pyridinyl)ethynyl]-N-[3-chloro-4-[[(3-fluorophenyl)methyl]oxy]phenyl]-4-pyrimidinamine 845657-82-1P, [6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methanol 845658-03-9P, 5-[[6-(Aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-

4-[(3-fluorobenzyl)oxy]phenyl]-4-pyrimidinamine 845658-04-0P, 5-[[6-(Aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-4-pyrimidinamine bis(fluoroacetate) 845658-22-2P, 4-Amino-2-[[4-[[3-chloro-4-[(4-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]pyrimidine-5-carbonitrile
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrimidines as ErB kinase inhibitors)

RN 845657-38-7 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(3-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845657-39-8 CAPLUS
CN Acetamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-51-4 CAPLUS
CN Carbamic acid, [[3-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 845657-55-8 CAPLUS
CN 2-Furancarboxaldehyde, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-72-9 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(6-amino-2-pyridinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845657-82-1 CAPLUS
CN 2-Pyridinemethanol, 6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845658-03-9 CAPLUS
CN 4-Pyrimidinamine, 5-[2-[6-(aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845658-04-0 CAPLUS
CN 4-Pyrimidinamine, 5-[2-[6-(aminomethyl)-2-pyridinyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 845658-03-9
CMF C25 H19 Cl F N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 845658-22-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-[2-[4-[[3-chloro-4-[(4-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



IT 845656-87-3P, 2-Benzyl-N-[5-((E)-2-phenylethenyl)pyrimidin-4-yl]-1H-benzimidazol-5-amine 845656-88-4P, 2-Benzyl-N-[5-[(E)-2-(thien-3-yl)ethenyl]pyrimidin-4-yl]-1H-benzimidazol-5-amine 845656-89-5P, 2-Benzyl-N-[5-[(E)-2-(1H-pyrazol-4-yl)ethenyl]pyrimidin-4-yl]-1H-benzimidazol-5-amine 845656-90-8P, 3-[(E)-2-[4-[(2-Benzyl-1H-benzimidazol-5-yl)amino]pyrimidin-5-yl]ethenyl]-N-methylbenzamide 845656-92-0P, 2-Benzyl-N-[5-[(E)-2-(thien-3-yl)ethenyl]pyrimidin-4-yl]-1,3-benzothiazol-5-amine 845656-94-2P, 1-Benzyl-N-[5-[(E)-2-(pyridin-3-yl)ethenyl]pyrimidin-4-yl]-1H-indazol-5-amine 845656-96-4P, 1-Benzyl-N-[5-[(E)-2-(pyridin-4-yl)ethenyl]pyrimidin-4-yl]-1H-indazol-5-amine 845656-98-6P, 2-[(E)-2-[4-[(1-Benzyl-1H-indazol-5-yl)amino]pyrimidin-5-yl]ethenyl]pyridin-3-ol 845657-00-3P, 1-Benzyl-N-[5-[(E)-2-(1H-pyrazol-4-yl)ethenyl]pyrimidin-4-yl]-1H-indazol-5-amine 845657-02-5P, N-[5-[(E)-2-(2-Aminopyrimidin-5-yl)ethenyl]pyrimidin-4-yl]-1-benzyl-1H-indazol-5-amine 845657-03-6P, N-[3-[(E)-2-[4-[(1-Benzyl-1H-indazol-5-yl)amino]pyrimidin-5-yl]ethenyl]phenyl]acetamide 845657-06-9P, N-(4-Phenoxyphenyl)-5-((E)-2-phenylethenyl)pyrimidin-4-amine monohydrochloride 845657-08-1P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(E)-2-(pyridin-3-yl)ethenyl]pyrimidin-4-amine 845657-10-5P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(E)-2-(pyridin-4-yl)ethenyl]pyrimidin-4-amine 845657-12-7P, 2-[(E)-2-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethenyl]pyridin-3-ol 845657-13-8P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(E)-2-(thien-2-yl)ethenyl]pyrimidin-4-amine 845657-15-0P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(E)-2-(thien-3-yl)ethenyl]pyrimidin-4-amine 845657-16-1P, 5-[(E)-2-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethenyl]pyrimidin-2-amine 845657-17-2P, N-[3-Chloro-4-[(3-

fluorobenzyl)oxy]phenyl]-5-[(E)-2-(1H-pyrazol-4-yl)ethenyl]pyrimidin-4-amine 845657-18-3P, N-[3-[(E)-2-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethenyl]phenyl]acetamide 845657-19-4P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]pyrimidin-4-amine 845657-20-7P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-((E)-2-phenylethenyl)pyrimidin-4-amine 845657-21-8P, N-[5-[(E)-2-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethenyl]pyridin-2-yl]acetamide 845657-23-0P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(pyridin-3-yl)ethynyl]pyrimidin-4-amine 845657-24-1P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(1-methyl-1H-imidazol-5-yl)ethynyl]pyrimidin-4-amine 845657-26-3P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(1H-pyrazol-4-yl)ethynyl]pyrimidin-4-amine 845657-27-4P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(pyrimidin-5-yl)ethynyl]pyrimidin-4-amine 845657-28-5P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(1,3-thiazol-2-yl)ethynyl]pyrimidin-4-amine 845657-30-9P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(thien-3-yl)ethynyl]pyrimidin-4-amine 845657-31-0P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[2-(morpholin-4-yl)pyrimidin-4-yl]ethynyl]pyrimidin-4-amine 845657-32-1P, N-[3-Chloro-4-[[(3-fluorophenyl)methyl]oxy]phenyl]-5-[(2-pyrimidinyl)ethynyl]-4-pyrimidinamine 845657-34-3P, 5-[(6-Amino-3-pyridinyl)ethynyl]-N-[3-chloro-4-[[(3-fluorophenyl)methyl]oxy]phenyl]-4-pyrimidinamine 845657-35-4P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(3-fluorophenyl)ethynyl]pyrimidin-4-amine 845657-36-5P, 4-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenol 845657-37-6P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(6-methoxypyridin-2-yl)ethynyl]pyrimidin-4-amine 845657-40-1P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]ethanethioamide 845657-41-2P, 2-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]benzonitrile 845657-42-3P, 3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]benzonitrile 845657-43-4P, 3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]benzaldehyde 845657-45-6P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-(phenylethynyl)pyrimidin-4-ylamine 845657-47-8P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(pyridin-2-yl)ethynyl]pyrimidin-4-amine 845657-48-9P, 5-[(4-Aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]pyrimidin-4-amine 845657-49-0P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-3-(methylthio)propanamide 845657-50-3P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[1-[(4-methylphenyl)sulfonyl]-1H-indol-6-yl]ethynyl]pyrimidin-4-amine 845657-52-5P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]guanidine 845657-53-6P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]benzyl]acetamide 845657-54-7P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[3-[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]pyrimidin-4-amine 845657-56-9P, 3-[[[5-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]-2-furyl]methyl]amino]propanenitrile 845657-57-0P, [5-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-

yl]ethynyl]-2-furyl]methanol 845657-58-1P, [4-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]-1,3-thiazol-2-yl]methanol 845657-59-2P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]pyrimidin-4-amine 845657-61-6P, 2-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]benzaldehyde 845657-62-7P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]ethynyl]pyrimidin-4-amine 845657-63-8P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-2-(2-methoxyethoxy)acetamide 845657-64-9P, N-[3-[[4-[(2-Benzyl-1H-benzimidazol-5-yl)amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-65-0P, N1-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-β-alaninamide 845657-66-1P, N-[3-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-2-(methylsulfonyl)acetamide 845657-67-2P, N-[3-[[4-[(4-Benzylphenyl)amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-68-3P, N-[3-[[4-[(4-Phenoxyphenyl)amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-69-4P, N-[3-[[4-[(1-Benzyl-1H-indazol-5-yl)amino]pyrimidin-5-yl]ethynyl]phenyl]acetamide 845657-70-7P, 1-Benzyl-N-[5-(phenylethynyl)pyrimidin-4-yl]-1H-indol-5-amine 845657-74-1P, N-[6-[2-[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]pyrimidin-5-yl]ethynyl]pyridin-2-yl]acetamide 845657-76-3P, 2-Chloro-N-[6-[[4-[3-chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-2,2-difluoroacetamide 845657-77-4P, N-[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-4-(dimethylamino)butanamide 845657-78-5P, Methyl 4-[[6-[[4-[3-chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]amino]-4-oxobutanoate 845657-80-9P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[2-(methylsulfonyl)ethyl]amino]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-84-3P, 2-[[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl](methyl)amino]ethanol 845657-85-4P, 3-[[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amino]propanenitrile 845657-86-5P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[[2-(4-morpholinyl)ethyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-88-7P, N-[2-[[[6-[2-[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amino]ethyl]acetamide 845657-90-1P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-92-3P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[(methylamino)methyl]pyridin-2-yl]ethynyl]-4-pyrimidinamine 845657-94-5P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-(methoxymethyl)-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-95-6P , N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[2-(methylsulfanyl)-4-pyrimidinyl]ethynyl]-4-pyrimidinamine 845657-97-8P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[(dimethylamino)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-98-9P, N-Benzyl-N-[[6-[[4-[3-chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amine 845658-00-6P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845658-05-1P, 1-[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-

5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-3-(2-cyanoethyl)urea
845658-07-3P, 3-[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-1-(2-hydroxyethyl)-1-methylurea
845658-08-4P, 1-[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-3-[2-(methylsulfonyl)ethyl]urea
845658-10-8P, 1-[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-3-[2-(4-morpholinyl)ethyl]urea
845658-12-0P, 1-[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-3-methylurea
845658-14-2P, 1-[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-3-(2-methoxyethyl)urea
845658-15-3P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[(1-piperidinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
845658-16-4P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
845658-18-6P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[(4-morpholinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
845658-19-7P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[(1-pyrrolidinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
845658-20-0P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[(1-piperazinyl)methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine
845658-24-4P, 2-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]-4-[[2-(methylsulfonyl)ethyl]amino]pyrimidine-5-carbonitrile 845658-25-5P, 4-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]pyrimidin-2-amine
845658-26-6P, N-[6-[[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]pyrimidin-5-yl]ethynyl]pyridin-2-yl]-2,2,2-trifluoroacetamide 845658-28-8P, N-(4-Phenoxyphenyl)-5-((E)-2-phenylethenyl)pyrimidin-4-amine 845658-30-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidines as ErB kinase inhibitors)

RN 845656-87-3 CAPLUS
CN 1H-Benzimidazol-6-amine, N-[5-[(1E)-2-phenylethenyl]-4-pyrimidinyl]-2-(phenylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 845656-88-4 CAPLUS
CN 1H-Benzimidazol-6-amine, 2-(phenylmethyl)-N-[5-[(1E)-2-(3-thienyl)ethenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845656-89-5 CAPLUS
CN 1H-Benzimidazol-6-amine, 2-(phenylmethyl)-N-[5-[(1E)-2-(1H-pyrazol-4-yl)ethenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845656-90-8 CAPLUS
CN Benzamide, N-methyl-3-[(1E)-2-[4-[[2-(phenylmethyl)-1H-benzimidazol-6-yl]amino]-5-pyrimidinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845656-92-0 CAPLUS
CN 5-Benzothiazolamine, 2-(phenylmethyl)-N-[5-[(1E)-2-(3-thienyl)ethenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845656-94-2 CAPLUS
CN 1H-Indazol-5-amine, 1-(phenylmethyl)-N-[5-[(1E)-2-(3-pyridinyl)ethenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845656-96-4 CAPLUS
CN 1H-Indazol-5-amine, 1-(phenylmethyl)-N-[5-[(1E)-2-(4-pyridinyl)ethenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845656-98-6 CAPLUS
CN 3-Pyridinol, 2-[(1E)-2-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-5-pyrimidinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-00-3 CAPLUS
CN 1H-Indazol-5-amine, 1-(phenylmethyl)-N-[5-[(1E)-2-(1H-pyrazol-4-yl)ethenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-02-5 CAPLUS
CN 1H-Indazol-5-amine, N-[5-[(1E)-2-(2-amino-5-pyrimidinyl)ethenyl]-4-pyrimidinyl]-1-(phenylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-03-6 CAPLUS
CN Acetamide, N-[3-[(1E)-2-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-5-pyrimidinyl]ethenyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-06-9 CAPLUS
CN 4-Pyrimidinamine, N-(4-phenoxyphenyl)-5-[(1E)-2-phenylethenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 845657-08-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1E)-2-(3-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-10-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1E)-2-(4-pyridinyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-12-7 CAPLUS
CN 3-Pyridinol, 2-[(1E)-2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-13-8 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1E)-2-(2-thienyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-15-0 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1E)-2-(3-thienyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-16-1 CAPLUS
CN 4-Pyrimidinamine, 5-[(1E)-2-(2-amino-5-pyrimidinyl)ethenyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-17-2 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1E)-2-(1H-pyrazol-4-yl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-18-3 CAPLUS
CN Acetamide, N-[3-[(1E)-2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethenyl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-19-4 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-20-7 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1E)-2-phenylethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-21-8 CAPLUS
CN Acetamide, N-[5-[(1E)-2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethenyl]-2-pyridinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845657-23-0 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-pyridinyl)ethynyl]- (CA INDEX NAME)



RN 845657-24-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(1-methyl-1H-imidazol-5-yl)ethynyl]- (CA INDEX NAME)



RN 845657-26-3 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(1H-pyrazol-4-yl)ethynyl]- (CA INDEX NAME)



RN 845657-27-4 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(5-pyrimidinyl)ethynyl]- (CA INDEX NAME)



RN 845657-28-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-thiazolyl)ethynyl]- (CA INDEX NAME)



RN 845657-30-9 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-thienyl)ethynyl]- (CA INDEX NAME)



RN 845657-31-0 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[2-(4-morpholinyl)-4-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-32-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-pyrimidinyl)ethynyl]- (CA INDEX NAME)



RN 845657-34-3 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(6-amino-3-pyridinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845657-35-4 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(3-fluorophenyl)ethynyl]- (CA INDEX NAME)



RN 845657-36-5 CAPLUS
CN Phenol, 4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-37-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(6-methoxy-2-pyridinyl)ethynyl]- (CA INDEX NAME)



RN 845657-40-1 CAPLUS
CN Ethanethioamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-41-2 CAPLUS
CN Benzonitrile, 2-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-42-3 CAPLUS
CN Benzonitrile, 3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-43-4 CAPLUS
CN Benzaldehyde, 3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-45-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-(2-phenylethynyl)- (CA INDEX NAME)



RN 845657-47-8 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-pyridinyl)ethynyl]- (CA INDEX NAME)



RN 845657-48-9 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(4-aminophenyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845657-49-0 CAPLUS
CN Propanamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino

]-5-pyrimidinyl]ethynyl]phenyl]-3-(methylthio)- (CA INDEX NAME)



RN 845657-50-3 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[1-[(4-methylphenyl)sulfonyl]-1H-indol-6-yl]ethynyl]- (CA INDEX NAME)



RN 845657-52-5 CAPLUS
CN Guanidine, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-53-6 CAPLUS
CN Acetamide, N-[[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]methyl]- (CA INDEX NAME)



RN 845657-54-7 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[3-[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)



RN 845657-56-9 CAPLUS
CN Propanenitrile, 3-[[[5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-furanyl]methyl]amino]- (CA INDEX NAME)



RN 845657-57-0 CAPLUS
CN 2-Furanmethanol, 5-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-58-1 CAPLUS
CN 2-Thiazolemethanol, 4-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-59-2 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(1,2,3,4-tetrahydro-7-isoquinolinyl)ethynyl]- (CA INDEX NAME)



RN 845657-61-6 CAPLUS
CN Benzaldehyde, 2-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-62-7 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]ethynyl]- (CA INDEX NAME)



RN 845657-63-8 CAPLUS
CN Acetamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)



RN 845657-64-9 CAPLUS
CN Acetamide, N-[3-[2-[4-[[2-(phenylmethyl)-1H-benzimidazol-6-yl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-65-0 CAPLUS
CN Propanamide, 3-amino-N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-66-1 CAPLUS
CN Acetamide, N-[3-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-2-(methylsulfonyl)- (CA INDEX NAME)



RN 845657-67-2 CAPLUS
CN Acetamide, N-[3-[2-[4-[[4-(phenylmethyl)phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-68-3 CAPLUS
CN Acetamide, N-[3-[2-[4-[(4-phenoxyphenyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-69-4 CAPLUS
CN Acetamide, N-[3-[2-[4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 845657-70-7 CAPLUS
CN 1H-Indol-5-amine, N-[5-(2-phenylethynyl)-4-pyrimidinyl]-1-(phenylmethyl)-
(CA INDEX NAME)



RN 845657-74-1 CAPLUS
CN Acetamide, N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-
5-pyrimidinyl]ethynyl]-2-pyridinyl]- (CA INDEX NAME)



RN 845657-76-3 CAPLUS
CN Acetamide, 2-chloro-N-[6-[2-[4-[[3-chloro-4-[(3-
fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-2,2-
difluoro- (CA INDEX NAME)



RN 845657-77-4 CAPLUS
CN Butanamide, N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-4-(dimethylamino)- (CA INDEX NAME)



RN 845657-78-5 CAPLUS
CN Butanoic acid, 4-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]amino]-4-oxo-, methyl ester (CA INDEX NAME)



RN 845657-80-9 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[[2-(methylsulfonyl)ethyl]amino]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845657-84-3 CAPLUS
CN Ethanol, 2-[[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]methylamino]- (CA INDEX NAME)



RN 845657-85-4 CAPLUS
CN Propanenitrile, 3-[[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amino]- (CA INDEX NAME)



RN 845657-86-5 CAPLUS
CN 4-Morpholineethanamine, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]- (CA INDEX NAME)



RN 845657-88-7 CAPLUS
CN Acetamide, N-[2-[[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]amino]ethyl]- (CA INDEX NAME)



RN 845657-90-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845657-92-3 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[(methylamino)methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845657-94-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(methoxymethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845657-95-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[2-(methylthio)-4-pyrimidinyl]ethynyl]- (CA INDEX NAME)



RN 845657-97-8 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[(dimethylamino)methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845657-98-9 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[[(phenylmethyl)amino]methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-00-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-05-1 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-(2-cyanoethyl)- (CA INDEX NAME)



RN 845658-07-3 CAPLUS
CN Urea, N'-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)



RN 845658-08-4 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)



RN 845658-10-8 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 845658-12-0 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-methyl- (CA INDEX NAME)



RN 845658-14-2 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)



RN 845658-15-3 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(1-piperidinylmethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-16-4 CAPLUS

CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-18-6 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(4-morpholinylmethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-19-7 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(1-pyrrolidinylmethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-20-0 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-(1-piperazinylmethyl)-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-24-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-4-[[2-(methylsulfonyl)ethyl]amino]- (CA INDEX NAME)



RN 845658-25-5 CAPLUS
CN 4-Pyrimidinamine, 5-[2-(2-amino-4-pyrimidinyl)ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845658-26-6 CAPLUS
CN Acetamide, N-[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 845658-28-8 CAPLUS
CN 4-Pyrimidinamine, N-(4-phenoxyphenyl)-5-[(1E)-2-phenylethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 845658-30-2 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(2-thienyl)ethynyl]- (CA INDEX NAME)



IT 845658-58-4P, 5-[[3-(Aminomethyl)phenyl]ethynyl]-N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]pyrimidin-4-amine 845658-77-7P, Di(tert-butyl)[6-[[4-[3-chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl] methyl imidodicarbonate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrimidines as ErB kinase inhibitors)
RN 845658-58-4 CAPLUS
CN 4-Pyrimidinamine, 5-[2-[3-(aminomethyl)phenyl]ethynyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)



RN 845658-77-7 CAPLUS
CN Imidodicarbonic acid, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:547247 CAPLUS
DN 141:225454
TI Tandem Michael-addition/cyclization synthesis and EGFR kinase inhibition activity of pyrido[2,3-d]pyrimidin-7(8H)-ones
AU Boros, Eric E.; Wood, Edgar R.; McDonald, O. Bradley; Spitzer, Timothy D.; Sefler, Andrea M.; Reep, Bryan R.; Thompson, James B.
CS Medicinal Chemistry, GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709, USA
SO Journal of Heterocyclic Chemistry (2004), 41(3), 355-358
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
OS CASREACT 141:225454
AB 5-Methoxy (I) and 5-anilinopyrido[2,3-d]pyrimidin-7(8H)-ones were obtained by a tandem Michael addition-cyclization reaction of methanol and anilines with Me [4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)pyrimidin-5-yl]propynoate (II). This methodol. accomplishes Michael-addition and pyridopyrimidinone ring formation in one pot and affords the desired products in reasonable yield without chromatog. II did not react with 4-cyanoaniline under these conditions. Reaction of II with 2-aminopyridine gave an unexpected arylpyrido[2,3-d]pyrimidinone in 58% yield and reaction of II with imidazole afforded Michael-adduct in 69% yield. I and II were submicromolar inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase.
IT 746677-62-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(tandem Michael-addition/cyclization synthesis and EGFR kinase inhibition activity of pyrido[2,3-d]pyrimidin-7(8H)-ones)
RN 746677-62-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]-3-(1H-imidazol-1-yl)-, methyl ester, (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:90025 CAPLUS
DN 136:151172
TI Preparation of 5-(arylalkynyl)pyrimidines having neurotrophic activity for the treatment of neurodegerative and other neurological disorders
IN Beauchamp, Lilia; Krenitsky, Thomas A.; Kelley, James L.
PA Krenitsky Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English

closest reference

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002008205	A1	20020131	WO 2001-US23088	20010720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2416442	A1	20020131	CA 2001-2416442	20010720
	AU 2001073574	A	20020205	AU 2001-73574	20010720
	EP 1303495	A1	20030423	EP 2001-952859	20010720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004504386	T	20040212	JP 2002-514111	20010720
	US 20040087789	A1	20040506	US 2003-333447	20030627
	US 7205297	B2	20070417		
PRAI	US 2000-220348P	P	20000724		
	WO 2001-US23088	W	20010720		

OS MARPAT 136:151172
AB Title compds. I [wherein Z = O, NH, or S; m = 0-1; R1 = (un)substituted (alkyl)a((hetero)cycloalkyl or (hetero)aryl)b(alkyl)c; a, b, and c = independently 0-1 and a + b + c ≥ 1, with provisos; R2 = H, NH2, or NHCOR3; R3 = H or alkyl; X = (un)substituted aryl; and pharmaceutically acceptable esters, amides, salts, or solvates thereof] were prepared Pharmaceutical compns. which contain I, methods for their preparation, and their use in therapy, particularly in the treatment of neurodegenerative or other neurol. disorders of the central and peripheral nervous systems, including age related cognitive disorders such as senility and Alzheimer's disease, nerve injuries, peripheral neuropathies, and seizure disorders such as epilepsy, are disclosed. For example, 4-chloro-5-(4-chlorophenylethynyl)pyrimidine (preparation given) was coupled with (trans)-4-aminocyclohexanol•HCl using TEA and MeCN in CH2Cl2 to afford II. The latter increased the choline acetyltransferase (ChAT) activity relative to nerve growth factor (NGF) alone with EC2x of 0.2 μM.
IT 393856-48-9P, 4-(4-Hydroxyanilino)-5-phenylethynylpyrimidine
393856-51-4P, 5-(4-Chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CNS agent; preparation of (arylalkynyl)pyrimidines having neurotrophic

activity for the treatment of neurodegenerative and other neurol. disorders)

RN 393856-48-9 CAPLUS

CN Phenol, 4-[[5-(2-phenylethynyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 393856-51-4 CAPLUS

CN Phenol, 4-[[5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)



IT 393857-20-0P, 4-(4-Hydroxyanilino)-5-phenylethynylpyrimidine hydrochloride 393857-23-3P, 5-(4-Chlorophenylethynyl)-4-(4-hydroxyanilino)pyrimidine hydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of (arylalkynyl)pyrimidines having neurotrophic activity for the treatment of neurodegenerative and other neurol. disorders)

RN 393857-20-0 CAPLUS

CN Phenol, 4-[[5-(2-phenylethynyl)-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 393857-23-3 CAPLUS

CN Phenol, 4-[[5-[2-(4-chlorophenyl)ethynyl]-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    50.01      232.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    -7.20       -7.20

STN INTERNATIONAL LOGOFF AT 23:58:16 ON 22 JUN 2008
```